<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03744013</url>
  </required_header>
  <id_info>
    <org_study_id>CL1104</org_study_id>
    <nct_id>NCT03744013</nct_id>
  </id_info>
  <brief_title>A Post Market Prospective Study of FORTIVA® 1mm Porcine Dermis</brief_title>
  <acronym>APPeaR</acronym>
  <official_title>A Post Market Prospective Study of FORTIVA® 1mm Porcine Dermis in Breast Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RTI Surgical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RTI Surgical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a post market prospective, multi-center study of up to 100 subjects undergoing
      post-mastectomy breast reconstruction (50 Fortiva® 1mm perforated and 50 Fortiva® 1mm
      non-perforated) at up to 10 clinical study sites in Europe.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">March 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>post market prospective, multi-center study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Fortiva® tissue matrix</measure>
    <time_frame>24 months</time_frame>
    <description>Safety will be evaluated by assessing the incidence of device and/or procedure related adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance of Fortiva® tissue matrix</measure>
    <time_frame>24 months</time_frame>
    <description>• Analysis of the subject's overall satisfaction with the breast reconstruction procedure will be assessed by obtaining subject's perception of the outcomes using the Breast-QTM - Reconstruction survey.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Mammoplasty</condition>
  <arm_group>
    <arm_group_label>Perforated</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fortiva® 1mm perforated ADM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-perforated</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fortiva® 1mm non-perforated ADM</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fortiva® 1mm</intervention_name>
    <description>Post mastectomy immediate reconstruction</description>
    <arm_group_label>Non-perforated</arm_group_label>
    <arm_group_label>Perforated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female 18 years or older

          2. A candidate for immediate breast reconstruction during post-skin sparing or
             nipple-sparing mastectomy (unilateral or bilateral)

          3. Estimated life expectancy &gt; 2 years

          4. Able and willing to return for all scheduled and required study visits

          5. Able to provide written informed consent for study participation

          6. Able to read, understand and complete study questionnaires

        Exclusion Criteria:

          1. Any of the conditions listed in the approved labeling as contraindicated

          2. Currently enrolled or plans to enroll in another clinical study that would affect the
             validity of the study

          3. Any patient that per the physician's judgement is not a good candidate for this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daryle Petersen</last_name>
    <role>Study Director</role>
    <affiliation>RTI Surgical Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Agaplesion Markus Krankenhaus</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frankfurt University Hospital</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Technical University, Munich</name>
      <address>
        <city>München</city>
        <zip>81664</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nightingale Breast Unit, Manchester University NHS Foundation Trust (MFT), Wythenshawe Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>November 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2018</study_first_posted>
  <last_update_submitted>December 9, 2019</last_update_submitted>
  <last_update_submitted_qc>December 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

